Section III: Molecular diagnostics in neuro-oncology

Current Problems in Cancer

Volumn 38, Issue 5, 2014, Pages 175-179

  Neill, Stewart G ^a   Fisher, Kevin E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BETA CATENIN; BRG1 PROTEIN; DICKKOPF 1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; SECRETED FRIZZLED RELATED PROTEIN 1; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR YAP1; TUMOR MARKER;

ARTICLE; ATRX GENE; BRAIN BIOPSY; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CHILDHOOD CANCER; CHROMOSOME 10Q; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 9Q; CHROMOSOME ARM; CHROMOSOME DELETION; CIC GENE; CODON; CYTOGENETICS; DNA METHYLATION; DNA REPAIR; FLUORESCENCE IN SITU HYBRIDIZATION; FUBP1 GENE; GAB1 GENE; GENE EXPRESSION; GENE SEQUENCE; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; ISOCHROMOSOME; ISOCHROMOSOME 17Q; KCNA1 GENE; MEDULLOBLASTOMA; MOLECULAR DIAGNOSIS; MONOSOMY; MONOSOMY 6; MULTIPLEX POLYMERASE CHAIN REACTION; NEUROLOGY; NEUROPATHOLOGY; NPR3 GENE; OLIGODENDROGLIOMA; ONCOGENE; ONCOLOGY; PILOCYTIC ASTROCYTOMA; PLEOMORPHIC XANTHOASTROCYTOMA; POINT MUTATION; POLYMERASE CHAIN REACTION; PROMOTER REGION; RHABDOID TUMOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMARCB1 GENE; TERATOMA; TUMOR BIOPSY; WILD TYPE; X CHROMOSOME; CENTRAL NERVOUS SYSTEM NEOPLASMS; GENETICS; NUCLEOTIDE SEQUENCE;

CENTRAL NERVOUS SYSTEM NEOPLASMS; DNA MUTATIONAL ANALYSIS; HUMANS; MEDICAL ONCOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 84909647355     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2014.08.006     Document Type: Article

References (31)

1. Appin C.L., Brat D.J. Molecular genetics of gliomas. Cancer J 2014, 20(1):66-72.
2. Yan H., Parsons D.W., Jin G., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360(8):765-773.
3. Dang L., White D.W., Gross S., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462(7274):739-744.
4. Zhang C., Moore L.M., Li X., Yung W.K., Zhang W. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro Oncol 2013, 15(9):1114-1126.
5. Jiao Y., Killela P.J., Reitman Z.J., et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012, 3(7):709-722.
6. Metellus P., Coulibaly B., Colin C., et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 2010, 120(6):719-729.
7. Sanson M., Marie Y., Paris S., et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009, 27(25):4150-4154.
8. Ohgaki H., Kleihues P. Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 2011, 28(3):177-183.
9. Watanabe T., Nobusawa S., Kleihues P., Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009, 174(4):1149-1153.
10. Perizzolo M., Winkfein B., Hui S., Krulicki W., Chan J.A., Demetrick D.J. IDH mutation detection in formalin-fixed paraffin-embedded gliomas using multiplex PCR and single-base extension. Brain Pathol 2012, 22(5):619-624.
11. Agarwal S., Sharma M.C., Jha P., et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro Oncol 2013, 15(6):718-726.
12. Nguyen D.N., Heaphy C.M., de Wilde R.F., et al. Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. Brain Pathol 2013, 23(3):237-243.
13. Cairncross G., Jenkins R. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J 2008, 14(6):352-357.
14. Esteller M., Hamilton S.R., Burger P.C., Baylin S.B., Herman J.G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999, 59(4):793-797.
15. Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343(19):1350-1354.
16. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997-1003.
17. Lin A., Rodriguez F.J., Karajannis M.A., et al. BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol 2012, 71(1):66-72.
18. Schindler G., Capper D., Meyer J., et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011, 121(3):397-405.
19. Myung J.K., Cho H., Park C.K., Kim S.K., Lee S.H., Park S.H. Analysis of the BRAF(V600E) mutation in central nervous system tumors. Transl Oncol 2012, 5(6):430-436.
20. Kieran M.W. Targeting BRAF in pediatric brain tumors. Am Soc Clin Oncol Educ Book 2014, 34:e436-e440.
21. Korshunov A., Meyer J., Capper D., et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 2009, 118(3):401-405.
22. Roth J.J., Santi M., Rorke-Adams L.B., et al. Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumors. Cancer Genet 2014, 207(4):111-123.
23. Tian Y., Rich B.E., Vena N., et al. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn 2011, 13(6):669-677.
24. Taylor M.D., Northcott P.A., Korshunov A., et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012, 123(4):465-472.
25. Kool M., Korshunov A., Remke M., et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012, 123(4):473-484.
26. Clifford S.C., Lusher M.E., Lindsey J.C., et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 2006, 5(22):2666-2670.
27. Hasselblatt M., Gesk S., Oyen F., et al. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am J Surg Pathol 2011, 35(6):933-935.
28. Schneppenheim R., Fruhwald M.C., Gesk S., et al. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet 2010, 86(2):279-284.
29. Haberler C., Laggner U., Slavc I., et al. Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. Am J Surg Pathol 2006, 30(11):1462-1468.
30. Judkins A.R., Mauger J., Ht A., Rorke L.B., Biegel J.A. Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol 2004, 28(5):644-650.
31. Behdad A., Perry A. Central nervous system primitive neuroectodermal tumors: a clinicopathologic and genetic study of 33 cases. Brain Pathol 2010, 20(2):441-450.